IRIDEX CORP
IRIDEX develops, manufactures, markets, sells and services ophthalmic laser systems and related instruments used by ophthalmologists to treat sight-threatening conditions, including glaucoma and retinal diseases. Its products include laser consoles, delivery devices and single-use probes. Product lines include the Cyclo G6 glaucoma system, IQ and PASCAL medical-retina systems, OcuLight surgical-retina lasers, and probes such as MicroPulse P3, G-Probe and EndoProbe. Its MicroPulse and Endpoint Management technologies offer optional treatment modes in select consoles alongside continuous-wave laser treatment. IRIDEX sells systems and consumable products, predominantly single-use laser probes and other instrumentation, and earns recurring income from repairs, service and extended service contracts. Ophthalmologists use its systems in hospitals, ambulatory surgical centers, offices and clinics. Sales are made through a direct sales force in the United States and Germany and through distributors in other international markets. IRIDEX is headquartered in Mountain View, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $IRIX in the last 7 days.
No SEC Form 4 filings for $IRIX in the last 30 days.
See all $IRIX insider activity →Iridex Corporation (IRIX) published a two-year study on glaucoma treatment using its MicroPulse Technology, showing significant intraocular pressure reduction and medication decrease. The study, led by Dr. Michele Lanza, was published in the International Journal of Ophthalmology and reported no complications. Iridex manufactures laser-based medical systems for glaucoma and retinal diseases.
Nippon Life bought $2.3M in Corebridge shares at $34.75 on average. Sonic Automotive's director acquired $67K in shares. IRIDEX's director accumulated shares at higher prices. Cloudflare's president sold $35.2M in shares. Rubrik's CTO sold $4.78M in shares. Kinetik Holdings' 10% owner sold $9.06M in shares. Diamondback Energy's director sold $6.12M in shares. Liquidia's director sold $6.39M in shares.
Lin Shih-Yao David purchased 350,557 indirectly-held shares of IRIDEX CORP (IRIX) at an average of $1.25 ($0.93–$1.49, $0.44M total) across 30 trades over 2025-12-03 to 2026-03-30.
Recent IRIX coverage spans insider activity, financial news and technology.
Positive trial data may lift investor sentiment and support near‑term price appreciation.
Significant insider accumulation may boost sentiment.
Insider buying may create modest upward pressure on IRIX.
Insider purchase suggests confidence, may create modest buying pressure.
Insider purchase may signal confidence, modestly supporting price.
AlphAI scores every news story that mentions IRIX with an AI model for sentiment and relevance, and aggregates insider trades from IRIDEX CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Iridex Corporation (IRIX) published a two-year study on glaucoma treatment using its MicroPulse Technology, showing significant intraocular pressure reduction and medication decrease. The study, led by Dr. Michele Lanza, was published in the International Journal of Ophthalmology and reported no complications. Iridex manufactures laser-based medical systems for glaucoma and retinal diseases.
Nippon Life bought $2.3M in Corebridge shares at $34.75 on average. Sonic Automotive's director acquired $67K in shares. IRIDEX's director accumulated shares at higher prices. Cloudflare's president sold $35.2M in shares. Rubrik's CTO sold $4.78M in shares. Kinetik Holdings' 10% owner sold $9.06M in shares. Diamondback Energy's director sold $6.12M in shares. Liquidia's director sold $6.39M in shares.
Lin Shih-Yao David purchased 350,557 indirectly-held shares of IRIDEX CORP (IRIX) at an average of $1.25 ($0.93–$1.49, $0.44M total) across 30 trades over 2025-12-03 to 2026-03-30.
Lin Shih-Yao David purchased 266,068 indirectly-held shares of IRIDEX CORP (IRIX) at an average of $1.03 ($0.88–$1.52, $0.27M total) across 30 trades over 2025-06-06 to 2025-12-01.
Lin Shih-Yao David purchased 570,184 indirectly-held shares of IRIDEX CORP (IRIX) at an average of $1.05 ($0.84–$1.22, $0.60M total) across 30 trades over 2025-03-25 to 2025-06-05.
Iridex Corporation (IRIX) has finished moving its manufacturing facility from Mountain View to San Jose, expecting $0.6M in annual cost savings. The company anticipates further savings as integration continues.
Dizon Romeo R (Chief Financial Officer) purchased 7,900 shares of IRIDEX CORP (IRIX) at $0.63 on 2026-09-16.
Dizon Romeo R (Chief Financial Officer) purchased 2,354 shares of IRIDEX CORP (IRIX) at $0.65 on 2026-09-14.
Dizon Romeo R (Chief Financial Officer) purchased 5,100 shares of IRIDEX CORP (IRIX) at $0.68 on 2026-09-10.
IRIDEX (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with Cyclo G6 product revenue up 19% but retina revenue down. Net loss was $1.3M. Management maintained full-year revenue guidance of $51M-$53M, excluding Middle East revenue, and expects low-double-digit glaucoma growth and low-single-digit retina growth in H2 2026.
